H.C. Wainwright reiterated a Buy rating and $24.00 price target on Galmed Pharmaceuticals (NASDAQ: GLMD) following the company's announcement that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change

Galmed Pharmaceuticals (GLMD) PT Lowered to $15 at SunTrust Robinson Humphrey, Keeps 'Buy'February 15, 2018 11:50 AM Pre-Open Movers 02/14: (FOSL) (IPCC) (CMG) Higher; (TTPH) (GLMD) (PIRS) Lower (more...)February 14, 2018 9:32 AM Pre-Open Movers 02/14: (FOSL) (IPCC) (CMG) Higher; (TTPH) (GLMD) (PIRS) Lower (more...)February 14, 2018 9:32 AM Maxim Group Downgrades Galmed Pharmaceuticals (GLMD) to HoldFebruary 14, 2018 9:06 AM Maxim Group Downgrades Galmed Pharmaceuticals (GLMD) to HoldFebruary 14, 2018 9:06 AM Galmed Pharma (GLMD) Says ARRIVE Trial Did Not Meet its Primary Endpoint February 14, 2018 7:18 AM Galmed Pharma (GLMD) Says ARRIVE Trial Did Not Meet its Primary Endpoint February 14, 2018 7:18 AM Galmed Announces ARRIVE Study DataFebruary 14, 2018 7:00 AM Galmed Announces ARRIVE Study DataFebruary 14, 2018 7:00 AM